Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Shannon Neville WestinKathleen MooreHye Sook ChonJung-Yun LeeJessica Thomes PepinMichael SundborgAyelet ShaiJoseph de la GarzaShin NishioMichael A GoldKe WangKristi McIntyreTodd D TillmannsStephanie V BlankJi-Hong LiuMichael McCollumFernando Contreras MejiaTadaaki NishikawaKathryn PenningtonZoltan NovakAndreia Cristina de MeloJalid SehouliDagmara Klasa-MazurkiewiczChristos PapadimitriouMarta Gil-MartinBirute BrasiunieneConor DonnellyPaula Michelle Del RosarioXiaochun LiuEls Van Nieuwenhuysennull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer.